Skip to main content

Table 2 Number and proportions of patients who achieved humoral response at week 5 by subgroup

From: Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy

  PCV-13 TTV
Overall baricitinib group (N = 106) 70 (68) 44 (43)
Concomitant corticosteroids
 Yes (N = 31) 22 (71) 16 (52)
 No (N = 72) 48 (67) 28 (39)
Age group
 Patients < 65 years (N = 80) 59 (74) 37 (46)
 Patients ≥ 65 years (N = 23) 11 (48) 7 (32)
SDAI prior to vaccination
 ≤ 3.3 (N = 21) 13 (62) 11 (55)
 > 3.3 and ≤ 11 (N = 47) 34 (72) 20 (43)
 > 11 (N = 32) 21 (66) 13 (41)
Baricitinib dose
 2 mg (N = 16) 11 (69) 5 (33)
 4 mg (N = 87) 59 (68) 39 (45)
  1. Data are reported as n (%). PCV-13 satisfactory humoral response defined as a ≥ 2-fold increase from baseline in antibody concentrations in ≥ 6 of the 13 pneumococcal serotypes. TTV satisfactory humoral response defined as a ≥ 4-fold increase from baseline in anti-tetanus concentration in patients with baseline anti-tetanus IgG concentration ≥ 0.1 IU/mL
  2. PCV-13 13-serotype pneumococcal conjugate vaccine, SDAI Simplified Disease Activity Index, TTV tetanus toxoid vaccine